Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.
When prescribing sodium-glucose cotransporter (SGLT) inhibitors, it is important to consider the impact on glycemic control, said Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.
Transcript:
Why is the range of effectiveness in the SGLT1/2 inhibitor in chronic kidney disease so important?
In patients with lowish GFR [glomerular filtration rate] and diabetes, SGLT2 inhibitors can be used. In fact, they do seem to provide clinical benefits. But in terms of glycemic control, which is why a lot of endocrinologists and primary care physicians are using diabetes drugs there, the current SGLT2 inhibitors that are available don't do a great job with respect to glycemic control. And we know glycemic control is important. Even though in recent years, we've focused on cardiovascular and cardiorenal outcomes, the glycemic control matters. It eventually will lead to microvascular complications, things like neuropathy and retinal damage if the glucose is just running out of control for too long. So there is a real benefit to glycemic control if it can be done safely. In patients with a diminished GFR, the SGLT2 inhibitors just aren't as effective as eliminating glucose through the urine because the GFR is low. But the SGLT1 inhibition from sotagliflozin could nicely fill in that gap, where it in the SCORED trial was seen, even in patients with low GFR, to provide a good degree of glycemic control similar to patients even with higher degrees of GFR with sotagliflozin. So that does seem to be a benefit that is specific to the SGLT1 mechanism of action.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More